| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | 呼吸系统
> 肺部疾病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Over 100,000 | National | Regularly | 119011106646 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 神经肌肉
> 肌营养不良症 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Regularly | 119021570524 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 肾脏
> 肾脏疾病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Do not know | National | Regularly | 119051003447 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee [PBAC] for the reimbursement of medicines relating to asthma, including some vaccines. | 呼吸系统
> 哮喘 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Over 100,000 | National | Regularly | 119051065145 |
| PBAC [Pharmaceutical Benefits Advisory Committee] comments. | 皮肤
> 特应性皮炎/湿疹 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Over 100,000 | National | Regularly | 119051082840 |
| HTA [Health Technology Assessment] — lived experience. | 呼吸系统
> 肺部疾病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Over 100,000 | National | Regularly | 119051865995 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 稀有
> 罕见病：遗传性 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Sometimes | 119054286714 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 胃肠道
> IBD | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Over 100,000 | National | Regularly | 119058351283 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | 心血管
> 心血管和心脏疾病 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | Do not know | International | Regularly | 119061299937 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | 心理健康
> 心理健康：大多数状况 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Sometimes | 119074282308 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | 呼吸系统
> 哮喘 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | Over 100,000 | National | Regularly | 119051065145 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 神经肌肉
> 肌营养不良症 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | National | Regularly | 119021570524 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. | 心理健康
> 心理健康：大多数状况 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 10,000 | National | Sometimes | 119074282308 |
| Regular advocacy and lobbying to all levels of government on new and current diabetes medications and technology. | 内分泌
> 糖尿病（1型和2型） | 影响政策和立法
> 影响医疗保健政策和立法 | Over 100,000 | National | Regularly | 119023443093 |
| We provide public comment to the Pharmaceutical Benefits Advisory Committee for the reimbursement of medicines relating to asthma, including some vaccines. We write and support submissions to the Therapeutic Goods Administration for changes to medicines. Asthma Australia will lobby government if a change that is made is not in the best interest of people with asthma. | 呼吸系统
> 哮喘 | 影响政策和立法
> 影响医疗保健政策和立法 | Over 100,000 | National | Regularly | 119051065145 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 胃肠道
> IBD | 影响政策和立法
> 影响医疗保健政策和立法 | Over 100,000 | National | Regularly | 119058351283 |
| Where possible, we add our advocacy voice to decision-makers. | 神经肌肉
> 肌营养不良症 | 影响政策和立法
> 影响医疗保健政策和立法 | 1,000 | National | Rarely | 119070072574 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 肾脏
> 肾脏疾病 | 影响政策和立法
> 参与公众听证会和咨询 | Do not know | National | Regularly | 119051003447 |
| Public submissions. | 医学研究
> 医学研究 | 影响政策和立法
> 参与公众听证会和咨询 | 100 | National | Sometimes | 119075599019 |
| Pre-Budget Submissions, Advocacy activities, Meetings. | 风湿性
> 风湿性疾病：大多数类型 | 影响政策和立法
> 动员议员和政治领导人 | Over 100,000 | National | Regularly | 119017682842 |
| Weight loss drugs, general medicine costs. | 患者权益倡导
> 患者权利 | 定价与可负担性倡导
> 倡导公平的药品定价 | 100,000 | National | Sometimes | 119055318270 |
| Involved in government [Australia] policy reviews - HTA review and Chronic Disease - submit responses to TGA [Therapeutic Goods Administration], MSAC [Medical Services Advisory Committee], and PBAC [Pharmaceutical Benefits Advisory Committee] in relation to sponsor requests. | 胃肠道
> IBD | 定价与可负担性倡导
> 倡导公平的药品定价 | Over 100,000 | National | Regularly | 119058351283 |
| Pricing. | 风湿性
> 狼疮 | 定价与可负担性倡导
> 倡导公平的药品定价 | 5,000 | International | Regularly | 119058972997 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 神经系统
> 神经系统：其他 | 定价与可负担性倡导
> 倡导公平的药品定价 | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | 传染性
> 免疫接种 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | 骨骼
> 进行性骨化性纤维发育不良（FOP） | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | National | Rarely | 119044789085 |
| Australia's PBS [Pharmaceutical Benefits Scheme] listings as an example. | 肾脏
> 肾脏疾病 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 5,000 | National | Regularly | 119050789619 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 稀有
> 罕见病：遗传性 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | National | Sometimes | 119054286714 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | 心理健康
> 心理健康：大多数状况 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 10,000 | National | Sometimes | 119074282308 |
| Work with PBAC [Pharmaceutical Benefits Advisory Committee], HTA [Health Technology Assessment], TGA [Therapeutic Goods Administration], and MSAC [Medical Services Advisory Committee], as well as patient groups and Medicines Australia Australia to advocate for access and equity for treatments and care. | 神经肌肉
> 肌营养不良症 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Regularly | 119021570524 |
| Weight loss drugs, general medicine costs. | 患者权益倡导
> 患者权利 | 改善访问路径
> 促进公平获取药品/医疗保健 | 100,000 | National | Sometimes | 119055318270 |
| Regulations and restrictions regarding prescribing of antivirals for COVID to our patient cohort [neurological conditions]. | 神经系统
> 神经系统：其他 | 改善访问路径
> 促进公平获取药品/医疗保健 | 5,000 | National | Rarely | 119056702514 |
| PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], PL [Prostheses List]. | 心血管
> 心血管和心脏疾病 | 改善访问路径
> 促进公平获取药品/医疗保健 | Do not know | International | Regularly | 119061299937 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 神经系统
> 神经系统：其他 | 改善访问路径
> 促进公平获取药品/医疗保健 | We do not communicate with patients directly | National | Regularly | 119069368666 |
| Through an HTA [Health Technology Assessment] implementation review. | 神经系统
> 神经系统：其他 | 改善访问路径
> 促进公平获取药品/医疗保健 | We do not communicate with patients directly | National | Regularly | 119069368666 |
| We will sometimes complete Consumer Comments for the Pharmaceutical Benefits Advisory Committee if we feel that an immunization should be federally funded on the National Immunization Program. | 传染性
> 免疫接种 | 改善访问路径
> 倡导更广泛的疫苗获取渠道 | Over 100,000 | National | Sometimes | 119022383972 |
| Access to Palovarotene [to reduce the formation of abnomal bone tissue in people with It is indicated for patients with the ultra-rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP)] via the PBS [Pharmaceutical Benefits Scheme] listing. | 骨骼
> 进行性骨化性纤维发育不良（FOP） | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 100 | National | Rarely | 119044789085 |
| Consumer feedback to PBAC [Pharmaceutical Benefits Advisory Committee], MSAC [Medical Services Advisory Committee], government consultations, and other organisations on behalf of those with kidney disease. | 肾脏
> 肾脏疾病 | 循证患者意见
> 利用患者洞察来指导决策 | Do not know | National | Regularly | 119051003447 |
| Lived experience submissions on new treatments and medicines, part of national working group looking at HTA reform, part of industry campaign to improve timeliness of HTA approval [Australia]. | 呼吸系统
> 肺部疾病 | 循证患者意见
> 利用患者故事和亲身经历叙述 | Over 100,000 | National | Regularly | 119011106646 |
| We support and advocate for enhancement of the involvement of patients/carers in Health Technology. We have been involved in the Co design group Enhancing Consumer involvement in Australian Health technology assessment and in the HTA Review process. | 癌症
> 癌症：大多数类型 | 循证患者意见
> 利用患者故事和亲身经历叙述 | We do not communicate with patients directly | Regional | Sometimes | 119031444677 |
| HTA [Health Technology Assessment] — lived experience. | 呼吸系统
> 肺部疾病 | 循证患者意见
> 利用患者故事和亲身经历叙述 | Over 100,000 | National | Regularly | 119051865995 |
| Our organisation exists to represent the interests of both community-led mental health service organisations and also the lived experience consumer community. A recent example of our work representing patient interests to regulators that are responsible for deciding drug pricing was recent correspondence we issued to the Australian Pharmaceutical Benefits Advisory Committee, requesting that a drug for the treatment of schizophrenia be listed on the Pharmaceutical Benefits Scheme. In this correspondence, we directly represented the views of patients and family and carers. | 心理健康
> 心理健康：大多数状况 | 循证患者意见
> 利用患者故事和亲身经历叙述 | 10,000 | National | Sometimes | 119074282308 |
| Pricing, clinical trials. | 风湿性
> 狼疮 | 诊断与药品配送
> 协作设计临床试验 | 5,000 | International | Regularly | 119058972997 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 稀有
> 罕见病：遗传性 | 诊断与药品配送
> 支持筛查和早期检测 | 1,000 | National | Sometimes | 119054286714 |
| We provide expertise to regulatory and funding decision-makers on topics like newborn screening, medicine listing, and model of care funding. | 稀有
> 罕见病：遗传性 | 机构治理
> 确保在政府咨询机构中的代表性 | 1,000 | National | Sometimes | 119054286714 |
| Preterm Infants Parents Association [PIPA] has representatives on numerous hospital and Queensland Health Department committees. | 儿童健康
> 新生儿 | 机构治理
> 确保在政府咨询机构中的代表性 | 5,000 | Regional | Regularly | 119074312093 |
| Through an HTA [Health Technology Assessment] implementation review, direct advocacy around drug access and pricing, part of roundtables to more effectively advocate patient interests for change. | 神经系统
> 神经系统：其他 | 机构治理
> 在多利益相关方网络中高效协作 | We do not communicate with patients directly | National | Regularly | 119069368666 |
互动
行动与倡导
14 提及
